First COVID-19 drug has been assessed by G-BA
The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It
Tag: AMNOG process
What is reference pricing?
If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,
Negotiated reimbursement price applicable 12 months after launch
The early benefit assessment – 7 new laws since AMNOG
Since 2011, 7 new laws were added to AMNOG to dictate the early benefit assessment of drugs. Therefore, it is often called
G-BA assessments of new indications
The AMNOG law dictates that every pharmaceutical product with a new chemical entity which received its marketing authorization on or after 1